ES2477877T3 - Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos - Google Patents

Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos Download PDF

Info

Publication number
ES2477877T3
ES2477877T3 ES08785441.0T ES08785441T ES2477877T3 ES 2477877 T3 ES2477877 T3 ES 2477877T3 ES 08785441 T ES08785441 T ES 08785441T ES 2477877 T3 ES2477877 T3 ES 2477877T3
Authority
ES
Spain
Prior art keywords
hydroxy vitamin
mammals
muscle mass
increase muscle
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08785441.0T
Other languages
English (en)
Other versions
ES2477877T5 (es
Inventor
Thau Kiong Chung
Benito Averion Oliveros
Francisco Feranil Penalba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39874890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2477877(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Application granted granted Critical
Publication of ES2477877T3 publication Critical patent/ES2477877T3/es
Publication of ES2477877T5 publication Critical patent/ES2477877T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de 25-hidroxi vitamina D3 para promover de forma no terapéutica la miogénesis en un mamífero al administrar de forma prenatal una cantidad suficiente de 25-hidroxi vitamina D3 al mamífero durante el período de hiperplasia de fibras musculares.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES08785441.0T 2007-08-07 2008-08-07 Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos Active ES2477877T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07015458 2007-08-07
EP07015458 2007-08-07
PCT/EP2008/006537 WO2009019027A1 (en) 2007-08-07 2008-08-07 Use of 25-hydroxy vitamin d3 to increase muscle mass in mammals

Publications (2)

Publication Number Publication Date
ES2477877T3 true ES2477877T3 (es) 2014-07-18
ES2477877T5 ES2477877T5 (es) 2018-09-21

Family

ID=39874890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08785441.0T Active ES2477877T5 (es) 2007-08-07 2008-08-07 Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos

Country Status (9)

Country Link
US (1) US20110124608A1 (es)
EP (1) EP2173356B2 (es)
JP (1) JP5509502B2 (es)
KR (1) KR101503948B1 (es)
CN (1) CN101778636B (es)
DK (1) DK2173356T4 (es)
ES (1) ES2477877T5 (es)
PL (1) PL2173356T5 (es)
WO (1) WO2009019027A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2688424T3 (es) * 2009-06-11 2018-11-02 Dsm Ip Assets B.V. Trigonelina como estimulante muscular
CN107232417B (zh) * 2017-06-28 2018-09-25 广西商大科技股份有限公司 一种母猪六段式营养全价饲料和投料方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
EP1516540B1 (en) * 2003-09-22 2012-09-26 DSM IP Assets B.V. Use of vitamin D compounds
EP1917071B1 (en) * 2005-08-18 2014-01-08 DSM IP Assets B.V. Use of 25-hydroxy vitamin d3 to improve male animal fertility
CA2624897C (en) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
WO2007059960A1 (en) † 2005-11-25 2007-05-31 Dsm Ip Assets B.V. Use of 25-hydroxy vitamin d3 to improve vitality of animals

Also Published As

Publication number Publication date
US20110124608A1 (en) 2011-05-26
KR101503948B1 (ko) 2015-03-18
KR20100053549A (ko) 2010-05-20
CN101778636B (zh) 2012-11-28
DK2173356T4 (en) 2018-08-13
WO2009019027A1 (en) 2009-02-12
ES2477877T5 (es) 2018-09-21
EP2173356A1 (en) 2010-04-14
EP2173356B2 (en) 2018-05-02
CN101778636A (zh) 2010-07-14
PL2173356T3 (pl) 2014-09-30
EP2173356B1 (en) 2014-04-16
JP2010535727A (ja) 2010-11-25
JP5509502B2 (ja) 2014-06-04
DK2173356T3 (da) 2014-07-07
PL2173356T5 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ECSP056082A (es) Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
AR062857A1 (es) Crema para bebidas
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
CR10987A (es) Composiciones dispersables en agua y los metodos para utilizar las composiciones dispersables en agua
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
UY28509A1 (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
CR6964A (es) Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasa
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
ES2517491T3 (es) Estabilizador de los vasos linfáticos
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
ES2477877T3 (es) Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos
MA33022B1 (fr) Composition à libération contrôlée pour produire une préparation à libération prolongée contenant de l'udénafil
DOP2010000361A (es) Dronedarona para la prevencion de la cardioversion
ES2526913T3 (es) Composición farmacéutica que contiene neurotoxina 2 botulínica
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
ES2533046T3 (es) Oleíl-fosfocolina